Comparison of the clinical efficacy of two different cabergoline regimens on prevention of ovarian hyperstimulation syndrome (OHSS)

Research Journal of Obstetrics and Gynecology

Volumn 4, Issue 2, 2011, Pages 51-58

  Zargar, Mahvash ^a   Nikbakht, Roshan ^a   Pourmatroud, Elham ^a   Ghasemi, Kimia ^a   Hemadi, Masoud ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cabergoline; Clinical features; Infertile women; Laboratory findings; Ovarian hyperstimulation syndrome; Sonographic findings

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; CREATININE;

ABDOMINAL CIRCUMFERENCE; ABDOMINAL PAIN; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASCITES; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DYSPNEA; ECHOGRAPHY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; INTRACYTOPLASMIC SPERM INJECTION; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OLIGURIA; ORGAN SIZE; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVARY SIZE; OVULATION INDUCTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT DURATION; WEIGHT GAIN;

EID: 82855180174     PISSN: 19947925     EISSN: 2077222X     Source Type: Journal    
DOI: 10.3923/rjog.2011.51.58     Document Type: Article

References (32)

1. Aboulghar, M.A. and R.T. Mansour, 2003. Ovarian hyperstimulation syndrome: Classifications and critical analysis of preventive measures. Hum. Reprod. Update, 9: 275-289.
2. Agrawal, R., S.L. Tan, S. Wild, P. Sladkevicius and L. Engmann et al., 1999. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil. Steril., 71: 287-293.
3. Ajonuma, L.C., 2008. Is Vascular Endothelial Growth Factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)?. Med. Hypotheses, 70: 1174-1178.
4. Alvarez, C., L. Martin-Bonamati, E. Novella-Maestre, R. Sanz and R. Gomez et al., 2007. Dopamine agonist cabergoline reduces hemocon centration and ascites in hyperstimulated women undergoing assisted reproduction. J. Clin. Endocrinol. Metab., 92: 2931-2937.
5. Ata, B., A. Seyhan, S. Orhaner and B. Urman, 2009. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil. Steril., 92: 1168-1168.
6. Basu, S., J.A. Nagy, S. Pal, E. Vasile and I.A. Eckelhoefer et al., 2001. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med., 7: 569-574.
7. Busso, C.E., J. Garcia-Velasco, R. Gomez, C. Alvarez, C. Simon and A. Pellicer, 2009. Symposium: Update on prediction and management of OHSS. Prevention of OHSS-dopamine agonists. Prevention of OHSS-dopamine agonists. Rep. Biomed. 19: 52-58.
8. Cristina, C., G. Diaz-Torga, A. Baldi, A. Gongora, M. Rubinstein, M.J. Low and D. Becu-Villalobos, 2005. Increased pituitary vascular endothelial growth factor: A in dopaminergic D2 receptor knockout female mice. Endocrinology, 146: 2952-2952.
9. Curran, M.P. and C.M. Perry, 2004. Cabergoline: A review of its use in the treatment of Parkinson's disease. Drugs, 64: 2125-2141.
10. Czeizel, E. Andrew, Puho, Erzsebe, Acs, Nandor, Banhidy and Ferenc, 2006. A population based case-control study of oral moroxydine, an antiviral agent treatment during pregnancy. Int. J. Pharmacol., 2: 188-192.
11. Delvigne, A. and S. Rosenberg, 2002. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum. Reprod. Update, 8: 559-577.
12. Eghoghosoa, A.R., O.L. Aderemi, S.A. Olufemi and O.I. Peter, 2011. Effect of angiotensin I-converting enzyme inhibitor, captopril, on body weight and food and water consumption in oral contraceptive-treated rats. Am. J. Biochem. Mol. Biol., 1: 95-100.
13. Ferrara, N. and W.J. Henzel, 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 161: 851-858.
14. Geva, E. and R.B. Jaffe, 2000. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil. Steril., 74: 429-438.
15. Golan, A. and A. Weissman, 2009. Symposium: Update on prediction and management of OHSS. A modern classification of OHSS. Reprod. Biomed. Online, 19: 28-32.
16. Gospodarowicz, D., J.A. Abraham and J. Schilling, 1989. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculostellate cells. Proc. Natl. Acad. Sci. USA., 86: 7311-7315.
17. Haghjooyjavanmard, S., M. Nematbakhsh and M. Soleimani, 2009. The effect of hypercholesterolemia on serum vascular endothelial growth factor and nitrite concentrations in early stage of atherosclerosis in rabbits. Pak. J. Nutr., 8: 86-89.
18. Jiann, L., L. Yu-Hung and S. Kok-Min, 2010. Failure of Gabergoline to prevent sever overian hyperstimulation syndrome in patients with extremely high estradiol levels. Int. J. Gynecol. Obstetrics, 108: 159-160.
19. Lee, A., L.K. Christenson, R.L. Stouffer, K.A. Burry and P.E. Patton, 1997. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil. Steril., 68: 305-311.
20. Manno, M., 2005. Can we eliminate severe ovarian hyperstimulation syndrome?. Comment. I. Hum. Reprod., 20: 2368-2370.
21. Nourizad, S., M. Anvari, H. Hasani and M. Salami, 2008. A critical period for deleterious effect of prenatal alcohol exposure on working memory. Int. J. Pharmacol., 4: 382-387.
22. Ohba, T., T. Ujioka, K. Ishikawa, N. Tanaka and H. Okamura, 2003. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication. Mol. Cell Endocrinol., 202: 47-52.
23. Pau, E., I. Alonso-Muriel, R. Gomez, E. Novella and A. Ruiz et al., 2006. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum. Reprod., 21: 1453-1460.
24. Pellicer, A., J. Martinez, S. Arcecarlos and V. Gomez-Gallego, 2010. Treatment and Pervention of ovarian Hyperstimulation Syndrome (OHSS) using a Dopamine agonist. Fering International Ceater, New York, USA.
25. Rafi, A., D. Ramakrishna, K. Sabitha, S. Mohanty and P. Rao, 2011. Serum copper and Vascular Endothelial Growth Factor (VEGF-A) in dysfunctional uterine bleeding. Am. J. Biochem. Mol. Biol., 1: 284-290.
26. Raji, Y., A.O. Morakinyo, O.S. Akinsomisoye, A.K. Oloyo, P.R.C. Esegbue-Peters and O.T. Kunle-Alabi, 2006. Evaluation of the abortifacient properties of chloroform extract of Carica papaya L. seed in female albino rats. Int. J. Pharmacol., 2: 20-23.
27. Rollene, N.L., M.H. Amols, S.B. Hudson and C.C. Coddington, 2009. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: A case series. Fertil. Steril., 92: 1169-1169.
28. Sarkar, C., D. Chakroborty, R.B. Mitra, S. Banerjee, P.S. Dasgupta and S. Basu, 2004. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK and focal adhesion kinase in endothelial cells. Am. J. Physiol. Heart Circ Physiol., 287: 1554-1560.
29. Yamamoto, S, I. Konishi, Y., Tsuruta, K. Nanbu and M. Mandai et al., 1997. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol. Endocrinol., 11: 371-381.
30. Yan, Z., H.A. Weich, W. Bernart, M. Breckwoldt and J. Neulen, 1993. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J. Clin. Endocrinol. Metab., 77: 1723-1725.
31. Youssef, M.A.F. M, M. van Wely, M.A. Hassan, H.G. Al-Inany, M. Mochtar, S. Khattab and F. van der Veen, 2010. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum. Reprod. Update, 16: 459-466.
32. Ziadat, A.H., 2010. Disabilities of children in correlation to the usage of hair dye among pregnant women. Int. J. Pharmacol., 6: 487-493.